Back to search
FDAFDA · Food and drugs·Recall number D-0060-2023

Timolol-Latanoprost (0.5/0.005%) ophthalmic drops, Compounded, 5 mL bottle, Imprimis Rx, Ledgewood, NJ.

Published November 23, 2022 · Recall initiated: November 9, 2022

Summary

FDA records drug Class II recall D-0060-2023, published November 23, 2022 and initiated November 9, 2022. Recalling firm: ImprimisRx NJ; Status: Terminated; Reported quantity: 960 bottles; Lot: Lot # 06272022@3, Exp. date 11/24/2022 Lot # 08302022@1, Exp. date 01/27/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Subpotent Drug: The batches contain less than 90% of the labeled amount of latanoprost.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
ImprimisRx NJ
Distributor
Nationwide in the USA
Lot
Lot # 06272022@3, Exp. date 11/24/2022 Lot # 08302022@1, Exp. date 01/27/2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Timolol-Latanoprost (0.5/0.005%) ophthalmic drops, Compounded, 5 mL bottle, Imprimis Rx, Ledgewood, NJ. recalled?

Yes. FDA published recall D-0060-2023 on November 23, 2022. Reported hazard: Subpotent Drug: The batches contain less than 90% of the labeled amount of latanoprost.

What should I do if I have this product?

Voluntary: Firm initiated · Letter